-
1.发明授权Newcastle disease virus infectious clones, vaccines and new diagnostic assays 失效新城疫病毒感染性克隆，疫苗和新的诊断测定公开(公告)号：US07332169B2
公开(公告)日：2008-02-19
申请号：US10788232
申请日：2004-02-26
申请人： Bernardus Petrus Hubertus Peeters , Olav Sven de Leeuw , Guus Koch , Arnoud Leonard Josef Gielkens
发明人： Bernardus Petrus Hubertus Peeters , Olav Sven de Leeuw , Guus Koch , Arnoud Leonard Josef Gielkens
IPC分类号： A61K39/17 , A61K39/155 , A61K39/12 , C12Q1/68 , C12P39/00
CPC分类号： C07K14/005 , A61K2039/51 , C12N15/86 , C12N2760/18122 , C12N2760/18143
摘要： The invention relates to a process for generating infectious Newcastle disease virus (NDV) entirely from cloned full-length cDNA and to the use of vaccines and diagnostic assays generated with and derived from the process. The process offers the possibility to modify the NDV genome by means of genetic modification and allows for the introduction of mutations, deletions and/or insertions. The process can be used to modify the virulence of NDV, thus generating new attenuated live vaccines with enhanced properties. The process can be used to modify the antigenic make-up of NDV, to allow the generation of live NDV marker vaccines that can be serologically distinguished from NDV field strains.
摘要翻译： 本发明涉及一种完全由克隆的全长cDNA产生感染性新城疫病毒（NDV）的方法，以及使用由该方法产生和衍生的疫苗和诊断测定法。 该过程提供了通过遗传修饰来修饰NDV基因组并允许引入突变，缺失和/或插入的可能性。 该过程可用于修饰NDV的毒力，从而产生具有增强性质的新的减毒活疫苗。 该过程可用于修饰NDV的抗原构成，以产生可与NDV野毒株血清学区别的活NDV标记疫苗。
-
公开(公告)号：US5981502A
公开(公告)日：1999-11-09
申请号：US485001
申请日：1995-06-07
CPC分类号： C07K14/005 , A61K38/00 , A61K48/00 , C12N2750/12022
摘要： Novel proteins of the Chicken Anemia Virus are described and compositions for preventing or treating infections with that virus (CAV), in particular vaccines less pathogenic than the CAV itself, but yet leading to neutralizing antibodies in the immunized animal. Besides, there are described compositions containing antibodies against parts of the CAV for the control of infections with CAV and anti-idiotype antibodies. The invention also provides antibodies and test kits for the detection of CAV. Recombinant DNA molecules derived from CAV and host cells transfected therewith and vaccines based on these host cells are made possible by this invention. The invention also comprises living virus vaccines in which apiece of DAN is brought into a virus infectious to the host. Besides, the Invention provides uses of proteins of CAV in the induction of apoptosis, in particular in tumor cells. It further provides the induction of cell death by means of gene therapy.
摘要翻译： 描述了鸡贫血病毒的新型蛋白质，以及用于预防或治疗该病毒（CAV）的感染的组合物，特别是比CAV本身致病性更低的疫苗，但仍导致免疫动物中和抗体。 此外，还描述了含有抗CAV部分抗体以控制CAV和抗独特型抗体感染的抗体的组合物。 本发明还提供用于检测CAV的抗体和测试试剂盒。 衍生自CAV的重组DNA分子和转染的宿主细胞以及基于这些宿主细胞的疫苗通过本发明成为可能。 本发明还包括活体病毒疫苗，其中DAN的一部分被感染到宿主的病毒。 此外，本发明提供CAV蛋白质在凋亡诱导中的用途，特别是在肿瘤细胞中的用途。 它进一步提供通过基因治疗诱导细胞死亡。
-
3.发明授权Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor 失效基于病毒蛋白VP1，VP2和VP3或其编码的病毒序列的鸡贫血病毒突变体和疫苗和用途
公开(公告)号：US5952002A
公开(公告)日：1999-09-14
申请号：US911092
申请日：1997-08-14
IPC分类号： C12N15/02 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/395 , A61P31/12 , A61P35/00 , C07K14/01 , C12N5/10 , C12N7/00 , C12N15/09 , C12N15/34 , C12P21/08 , C12Q1/68 , C12R1/91 , A61K9/127
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N2750/10021 , C12N2750/10022
摘要： Novel proteins of the Chicken Anemia Virus are described and compositions for preventing or treating infections with that virus (CAV), in particular vaccines less pathogenic than the CAV itself, but yet leading to neutralizing antibodies in the immunized animal. Besides, there are described compositions containing antibodies against parts of the CAV for the control of infections with CAV and anti-idiotype antibodies. The invention also provides antibodies and test kits for the detection of CAV. Recombinant DNA molecules derived from CAV and host cells transfected therewith and vaccines based on these host cells are made possible by this invention. The invention also comprises living virus vaccines in which a piece of DNA is brought into a virus infectious to the host. Besides, the invention provides uses of proteins of CAV in the induction of apoptosis, in particular in tumor cells. It further provides the induction of cell death by means of gene therapy.
摘要翻译： 描述了鸡贫血病毒的新型蛋白质，以及用于预防或治疗该病毒（CAV）的感染的组合物，特别是比CAV本身致病性更低的疫苗，但仍导致免疫动物中和抗体。 此外，还描述了含有抗CAV部分抗体以控制CAV和抗独特型抗体感染的抗体的组合物。 本发明还提供用于检测CAV的抗体和测试试剂盒。 衍生自CAV的重组DNA分子和转染的宿主细胞以及基于这些宿主细胞的疫苗通过本发明成为可能。 本发明还包括活体病毒疫苗，其中一片DNA被带入感染宿主的病毒。 此外，本发明提供CAV蛋白在诱导凋亡中的用途，特别是在肿瘤细胞中的用途。 它进一步提供通过基因治疗诱导细胞死亡。
-
4.发明授权Newcastle disease virus infectious clones, vaccines and new diagnostic assays 失效新城疫病毒感染性克隆，疫苗和新的诊断测定公开(公告)号：US07547442B2
公开(公告)日：2009-06-16
申请号：US10824782
申请日：2004-04-15
申请人： Bernardus Petrus Hubertus Peeters , Olav Sven de Leeuw , Guus Koch , Arnoud Leonard Josef Gielkens
发明人： Bernardus Petrus Hubertus Peeters , Olav Sven de Leeuw , Guus Koch , Arnoud Leonard Josef Gielkens
CPC分类号： C07K14/005 , A61K2039/51 , C12N15/86 , C12N2760/18122 , C12N2760/18143
摘要： The invention relates to the process for generating infectious Newcastle disease virus (NDV) entirely from cloned full-length cDNA and to the use of vaccines and diagnostic assays generated with and derived from said process. The process offers the possibility to modify the NDV genome by means of genetic modification and allows the introduction of mutations, deletions and/or insertions. The process can be used to modify the virulence of NDV, thereby generating new attenuated live vaccines with enhanced properties. The process can be used to modify the antigenic make-up of NDV, thus allowing the generation of live NDV marker vaccines which can be serologically distinguished from NDV field strains.
摘要翻译： 本发明涉及完全由克隆的全长cDNA产生感染性新城疫病毒（NDV）的方法，以及使用由所述方法产生和衍生的疫苗和诊断测定法。 该过程提供了通过遗传修饰来修饰NDV基因组并允许引入突变，缺失和/或插入的可能性。 该方法可用于修饰NDV的毒力，从而产生具有增强性质的新的减毒活疫苗。 该过程可用于修饰NDV的抗原组成，从而允许产生可与NDV野毒株血清学区别的活NDV标记疫苗。
-
5.发明授权Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor 失效基于病毒蛋白VP1，VP2和VP3或其编码的病毒序列的鸡贫血病毒突变体和疫苗和用途公开(公告)号：US07427658B2
公开(公告)日：2008-09-23
申请号：US09740676
申请日：2000-12-18
IPC分类号： C07K7/08 , C07K14/01 , C07K16/46 , C07K19/00 , C12N15/62 , C12N1/21 , C12N5/10 , C12N15/34 , A61K39/12 , A61K39/395
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N15/86 , C12N2750/10022 , C12N2750/14143 , C12N2830/00 , C12N2830/60 , G01N33/56983
摘要： The coding information for three putative chicken anemia virus proteins (VP1, VP2, VP3) was inserted into a baculovirus vector and expressed in insect cells. Only lysates of insect cells which have synthesized equivalent amounts of all three recombinant CAV proteins or cells which synthesized mainly VP1 plus VP2 induced neutralizing antibodies directed against CAV in inoculated chickens. Progeny of those chickens were protected against clinical disease after CAV challenge. Inoculation of a mixture of lysates of cells that were separately infected with VP1-, VP2- and VP3-recombinant baculovirus did not induce significant levels of neutralizing antibody directed against CAV and their progeny were not protected against CAV challenge. Expression in the same cell of at least VP1 plus VP2 is required to obtain sufficient protection in chickens. Therefore, recombinant CAV proteins produced by baculovirus vectors can be used as a sub-unit vaccine against CAV infections.
摘要翻译： 将三种推定的鸡贫血病毒蛋白（VP1，VP2，VP3）的编码信息插入杆状病毒载体中，并在昆虫细胞中表达。 只有合成了相当量的所有三种重组CAV蛋白或主要合成VP1加VP2的细胞的昆虫细胞裂解液才能诱导接种鸡中抗CAV的中和抗体。 在CAV攻击后，这些鸡的后代受到临床疾病的保护。 分别感染VP1，VP2和VP3-重组杆状病毒的细胞裂解液的混合物接种不诱导针对CAV的显着水平的中和抗体，并且其后代不受CAV攻击的保护。 在至少VP1加VP2的相同细胞中的表达需要在鸡中获得足够的保护。 因此，由杆状病毒载体产生的重组CAV蛋白可用作针对CAV感染的亚单位疫苗。
-
6.发明授权Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1 VP2 and VP3 or sequences of that virus coding therefor 失效鸡贫血病毒突变体和基于病毒蛋白VP1 VP2和VP3或其编码的病毒序列的疫苗和用途
公开(公告)号：US5922600A
公开(公告)日：1999-07-13
申请号：US489666
申请日：1995-06-07
IPC分类号： A61K38/00 , A61K39/00 , A61K39/12 , A61P31/20 , C07H21/04 , C07K14/005 , C07K14/01 , C12N5/06 , C12N7/01 , C12N15/33 , C12N15/86 , C12Q1/70 , G01N33/569
CPC分类号： C07K14/005 , C12N15/86 , G01N33/56983 , A61K38/00 , A61K39/00 , C12N2750/10022 , C12N2750/14143 , C12N2830/00 , C12N2830/60
摘要： The coding information for three putative chicken anemia virus proteins (VP1, VP2, VP3) was inserted into a baculovirus vector and expressed in insect cells. The immunogenic properties of the chicken anemia virus (CAV) proteins produced separately or together in insect cell cultures were analyzed by inoculating them into chickens. Only lysates of insect cells which have synthesized equivalent amounts of all three recombinant CAV proteins or cells which synthesized mainly VP1 plus VP2 induced neutralizing antibodies directed against CAV in inoculated chickens. Progeny of those chickens were protected against clinical disease after CAV challenge. Inoculation of a mixture of lysates of cells that were separately infected with VP1- , VP2- and VP3-recombinant baculovirus did not induce significant levels of neutralizing antibody directed against CAV and their progeny were not protected against CAV challenge. Our results indicate that expression in the same cell of at least two CAV proteins, VP1 plus VP2, is required to obtain sufficient protection in chickens. Therefore, recombinant CAV proteins produced by baculovirus vectors can be used as a sub-unit vaccine against CAV infections.
摘要翻译： 将三种推定的鸡贫血病毒蛋白（VP1，VP2，VP3）的编码信息插入杆状病毒载体中，并在昆虫细胞中表达。 通过将它们接种到鸡中来分析在昆虫细胞培养物中单独或一起产生的鸡贫血病毒（CAV）蛋白的免疫原性。 只有合成了相当量的所有三种重组CAV蛋白或主要合成VP1加VP2的细胞的昆虫细胞裂解液才能诱导接种鸡中抗CAV的中和抗体。 在CAV攻击后，这些鸡的后代受到临床疾病的保护。 分别感染VP1，VP2和VP3-重组杆状病毒的细胞裂解液的混合物接种不诱导针对CAV的显着水平的中和抗体，并且其后代不受CAV攻击的保护。 我们的研究结果表明，需要在至少两种CAV蛋白VP1加VP2的相同细胞中表达以获得足够的鸡保护。 因此，由杆状病毒载体产生的重组CAV蛋白可用作针对CAV感染的亚单位疫苗。
-
7.发明申请Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor 失效基于病毒蛋白VP1，VP2和VP3或其编码的病毒序列的鸡贫血病毒突变体和疫苗和用途公开(公告)号：US20050100552A1
公开(公告)日：2005-05-12
申请号：US09740676
申请日：2000-12-18
申请人： Matheus Noteborn , Guus Koch
发明人： Matheus Noteborn , Guus Koch
IPC分类号： A61K38/00 , A61K39/00 , A61K39/12 , A61P31/20 , C07H21/04 , C07K14/005 , C07K14/01 , C12N5/06 , C12N7/01 , C12N15/33 , C12N15/86 , C12Q1/70 , G01N33/569
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N15/86 , C12N2750/10022 , C12N2750/14143 , C12N2830/00 , C12N2830/60 , G01N33/56983
摘要： The coding information for three putative chicken anemia virus proteins (VP1, VP2, VP3) was inserted into a baculovirus vector and expressed in insect cells. The immunogenic properties of the chicken anemia virus (CAV) proteins produced separately or together in insect-cell cultures were analyzed by inoculating them into chickens. Only lysates of insect cells which have synthesized equivalent amounts of all three recombinant CAV proteins or cells which synthesized mainly VP1 plus VP2 induced neutralizing antibodies directed against CAV in inoculated chickens. Progeny of those chickens were protected against clinical disease after CAV challenge. Inoculation of a mixture of lysates of cells that were separately infected with VP1-, VP2- and VP3-recombinant baculovirus did not induce significant levels of neutralizing antibody directed against CAV and their progeny were not protected against CAV challenge. Our results indicate that expression in the same cell of at least two CAV proteins, VP1 plus VP2, is required to obtain sufficient protection in chickens. Therefore, recombinant CAV proteins produced by baculovirus vectors can be used as a sub-unit vaccine against CAV infections.
摘要翻译： 将三种推定的鸡贫血病毒蛋白（VP1，VP2，VP3）的编码信息插入杆状病毒载体中，并在昆虫细胞中表达。 通过将它们接种到鸡中来分析在昆虫细胞培养物中单独或一起产生的鸡贫血病毒（CAV）蛋白的免疫原性。 只有合成了相当量的所有三种重组CAV蛋白或主要合成VP1加VP2的细胞的昆虫细胞裂解液才能诱导接种鸡中抗CAV的中和抗体。 在CAV攻击后，这些鸡的后代受到临床疾病的保护。 分别感染VP1，VP2和VP3-重组杆状病毒的细胞裂解液的混合物接种不诱导针对CAV的显着水平的中和抗体，并且其后代不受CAV攻击的保护。 我们的研究结果表明，需要在至少两种CAV蛋白VP1加VP2的相同细胞中表达以获得足够的鸡保护。 因此，由杆状病毒载体产生的重组CAV蛋白可用作针对CAV感染的亚单位疫苗。
-
8.发明授权Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1 VP2 and VP3 or sequences of that virus coding therefor 失效鸡贫血病毒突变体和基于病毒蛋白VP1 VP2和VP3或其编码的病毒序列的疫苗和用途公开(公告)号：US06217870B1
公开(公告)日：2001-04-17
申请号：US09057963
申请日：1998-04-09
IPC分类号： A61K3900
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N15/86 , C12N2710/14143 , C12N2750/10022 , C12N2750/10034 , C12N2830/00 , C12N2830/60 , G01N33/56983
摘要： The coding information for three putative chicken anemia virus proteins (VP1, VP2, VP3) was inserted into a baculovirus vector and expressed in insect cells. The immunogenic properties of the chicken anemia virus (CAV) proteins produced separately or together in insect-cell cultures were analyzed by inoculating them into chickens. Only lysates of insect cells which have synthesized equivalent amounts of all three recombinant CAV proteins or cells which synthesized mainly VP1 plus VP2 induced neutralizing antibodies directed against CAV in inoculated chickens. Progeny of those chickens were protected against clinical disease after CAV challenge. Inoculation of a mixture of lysates of cells that were separately infected with VP1-, VP2- and VP3-recombinant baculovirus did not induce significant levels of neutralizing antibody directed against CAV and their progeny were not protected against CAV challenge. Our results indicate that expression in the same cell of at least two CAV proteins, VP1 plus VP2, is required to obtain sufficient protection in chickens. Therefore, recombinant CAV proteins produced by baculovirus vectors can be used as a sub-unit vaccine against CAV infections.
摘要翻译： 将三种推定的鸡贫血病毒蛋白（VP1，VP2，VP3）的编码信息插入杆状病毒载体中，并在昆虫细胞中表达。 通过将它们接种到鸡中来分析在昆虫细胞培养物中单独或一起产生的鸡贫血病毒（CAV）蛋白的免疫原性。 只有合成了相当量的所有三种重组CAV蛋白或主要合成VP1加VP2的细胞的昆虫细胞裂解液才能诱导接种鸡中抗CAV的中和抗体。 在CAV攻击后，这些鸡的后代受到临床疾病的保护。 分别感染VP1，VP2和VP3-重组杆状病毒的细胞裂解液的混合物接种不诱导针对CAV的显着水平的中和抗体，并且其后代不受CAV攻击的保护。 我们的研究结果表明，需要在至少两种CAV蛋白VP1加VP2的相同细胞中表达以获得足够的鸡保护。 因此，由杆状病毒载体产生的重组CAV蛋白可用作针对CAV感染的亚单位疫苗。
-
9.发明授权Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor 失效基于病毒蛋白VP1，VP2和VP3或其编码的病毒序列的鸡贫血病毒突变体和疫苗和用途
公开(公告)号：US6162461A
公开(公告)日：2000-12-19
申请号：US482161
申请日：1995-06-07
IPC分类号： A61K38/00 , A61K39/00 , A61K39/12 , A61P31/20 , C07H21/04 , C07K14/005 , C07K14/01 , C12N5/06 , C12N7/01 , C12N15/33 , C12N15/86 , C12Q1/70 , G01N33/569 , A61K38/16 , A61K9/127 , C12N15/87
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N15/86 , C12N2750/10022 , C12N2750/14143 , C12N2830/00 , C12N2830/60 , G01N33/56983
摘要： The coding information for three putative chicken anemia virus proteins (VP1, VP2, VP3) was inserted into a baculovirus vector and expressed in insect cells. The immunogenic properties of the chicken anemia virus (CAV) proteins produced separately or together in insect-cell cultures were analyzed by inoculating them into chickens. Only lysates of insect cells which have synthesized equivalent amounts of all three recombinant CAV proteins or cells which synthesized mainly VP1 plus VP2 induced neutralizing antibodies directed against CAV in inoculated chickens. Progeny of those chickens were protected against clinical disease after CAV challenge. Inoculation of a mixture of lysates of cells that were separately infected with VP1-, VP2- and VP3-recombinant baculovirus did not induce significant levels of neutralizing antibody directed against CAV and their progeny were not protected against CAV challenge. Our results indicate that expression in the same cell of at least two CAV proteins, VP1 plus VP2, is required to obtain sufficient protection in chickens. Therefore, recombinant CAV proteins produced by baculovirus vectors can be used as a sub-unit vaccine against CAV infections.
摘要翻译： 将三种推定的鸡贫血病毒蛋白（VP1，VP2，VP3）的编码信息插入杆状病毒载体中，并在昆虫细胞中表达。 通过将它们接种到鸡中来分析在昆虫细胞培养物中单独或一起产生的鸡贫血病毒（CAV）蛋白的免疫原性。 只有合成了相当量的所有三种重组CAV蛋白或主要合成VP1加VP2的细胞的昆虫细胞裂解液才能诱导接种鸡中抗CAV的中和抗体。 在CAV攻击后，这些鸡的后代受到临床疾病的保护。 分别感染VP1，VP2和VP3-重组杆状病毒的细胞裂解液的混合物接种不诱导针对CAV的显着水平的中和抗体，并且其后代不受CAV攻击的保护。 我们的研究结果表明，需要在至少两种CAV蛋白VP1加VP2的相同细胞中表达以获得足够的鸡保护。 因此，由杆状病毒载体产生的重组CAV蛋白可用作针对CAV感染的亚单位疫苗。
-
10.发明授权Chicken anemia virus mutants and vaccines and uses based on the viral proteins VP1, VP2 and VP3 or sequences of that virus coding therefor 失效基于病毒蛋白VP1，VP2和VP3或其编码的病毒序列的鸡贫血病毒突变体和疫苗和用途
公开(公告)号：US6071520A
公开(公告)日：2000-06-06
申请号：US454121
申请日：1995-11-30
CPC分类号： C07K14/005 , C12N15/86 , G01N33/56983 , A61K38/00 , A61K39/00 , C12N2710/14143 , C12N2750/12022 , C12N2750/12034
摘要： Novel proteins of the Chicken Anemia Virus are described and compositions for preventing or treating infections with that virus (CAV), in particular vaccines less pathogenic than the CAV itself, but yet leading to neutralizing antibodies in the immunized animal. Besides, there are described compositions containing antibodies against parts of the CAV for the control of infections with CAV and anti-idiotype antibodies. The invention also provides antibodies and test kits for the detection of CAV. Recombinant DNA molecules derived from CAV and host cells transfected therewith and vaccines based on these host cells are made possible by this invention. The invention also comprises living virus vaccines in which a piece of DNA is brought into a virus infectious to the host. Besides, the invention provides uses of proteins of CAV in the induction of apoptosis, in particular in tumor cells. It further provides the induction of cell death by means of gene therapy.
摘要翻译： PCT No.PCT / NL94 / 00168 Sec。 371日期：1995年11月30日 102（e）1995年11月30日日期PCT 1994年7月19日PCT公布。 出版物WO95 / 03414 日期1995年2月2日描述了鸡贫血病毒的新蛋白质和用于预防或治疗该病毒感染（CAV）的组合物，特别是比CAV本身致病性更低的疫苗，但仍导致免疫动物中的抗体。 此外，还描述了含有抗CAV部分抗体以控制CAV和抗独特型抗体感染的抗体的组合物。 本发明还提供用于检测CAV的抗体和测试试剂盒。 衍生自CAV的重组DNA分子和转染的宿主细胞以及基于这些宿主细胞的疫苗通过本发明成为可能。 本发明还包括活体病毒疫苗，其中一片DNA被带入感染宿主的病毒。 此外，本发明提供CAV蛋白在诱导凋亡中的用途，特别是在肿瘤细胞中的用途。 它进一步提供通过基因治疗诱导细胞死亡。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.021 秒)
